AI-assisted scoping review of code sharing in clinical prediction model research. Publication: Nature Medicine. Dana-Farber Cancer Institute authors: ...
An investigational antibody-drug conjugate demonstrated clinically meaningful and durable responses in patients with platinum-resistant ovarian cancer, including patients whose tumors had low or no ...
If you are a journalist and have a question about this story, please call 617-632-4090 and ask to speak to a member of the media team, or email media@dfci.harvard.edu.
Rochelle G. Scheib, MD - Medical Oncology I absolutely love Dr. Scheib and am so very grateful she is my medical oncologist! She answers all of my & my husband's many questions in a clear, concise, ...
Dr. Brittany Bychkovsky is a medical oncologist at Dana-Farber Cancer Institute and an assistant professor at Harvard Medical School. She is a graduate of Harvard Medical School. She completed ...
Dana-Farber's Online Second Opinion Program for adult patients is powered by AccessHope. Once materials collection is complete, it typically takes 7 to 14 business days to receive your written online ...
Our Center for Esophageal and Gastric Cancer includes medical, surgical, and radiation oncologists, gastroenterologists, radiologists, and pathologists who improve the outcome for patients with ...
A rare inherited mutation in the Epidermal Growth Factor Receptor (EGFR) gene is associated with a 25-fold increased risk of lung cancer, according to a study by investigators at Dana-Farber Cancer ...
A large population-based study led by researchers at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center and Mass General Brigham suggests that genetic testing added to routine newborn ...
The U.S. Food and Drug Administration (FDA) has approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma who have received at least one ...
At the ASCO annual meeting, Dana-Farber’s Brian Wolpin, MD, MPH, will present positive results from the RASolute 302 trial showing a substantial prolongation of survival for patients with previously ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results